Q32 Bio (QTTB) Accumulated Expenses (2017 - 2026)

Q32 Bio's Accumulated Expenses history runs 10 years deep, the most recent figure standing at $3.8 million for Q1 2026.

• On a quarterly basis, Accumulated Expenses fell 28.26% year-over-year to $3.8 million in Q1 2026; TTM through Mar 2026 was $3.8 million, a 28.26% decrease from a year earlier, with the FY2025 full-year figure at $4.2 million, down 43.41% from the prior year.
• Accumulated Expenses fell to $3.8 million in Q1 2026 per QTTB's latest filing, from $4.2 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $19.8 million in Q1 2024 and bottomed at $2.5 million in Q1 2023.
• The 5-year median for Accumulated Expenses is $6.3 million (2022), against an average of $7.8 million.
• Across the five-year window, Accumulated Expenses soared 687.64% in 2024 and slumped 73.44% in 2025, its largest moves.
• Year by year, Accumulated Expenses stood at $18.7 million in 2022, then plunged by 47.83% to $9.8 million in 2023, then dropped by 23.39% to $7.5 million in 2024, then tumbled by 43.41% to $4.2 million in 2025, then retreated by 10.75% to $3.8 million in 2026.
• Per Business Quant, the three latest QTTB Accumulated Expenses figures stand at $3.8 million (Q1 2026), $4.2 million (Q4 2025), and $3.9 million (Q3 2025).